Repligen Corporation (RGEN) Presents at Stifel 2025 Healthcare Conference Transcript

Core Insights - The company reported a year-to-date non-COVID organic growth of 16% in Q3, indicating strong performance and satisfaction with results [1] - The diverse and innovative product portfolio is highlighted, with analytics and protein franchises exceeding expectations in Q3 [1] - The company aims to grow more than 5% above market growth, with projections indicating significant outperformance this year [1]